美国切片检查市场规模、份额、趋势分析报告：按类型、原因、部位和细分市场预测，2025-2030 年

美国切片检查市场的成长和趋势

根据 Grand View Research, Inc. 的一份新报告，美国癌症切片检查市场预计到 2030 年将达到 201.8 亿美元，2025 年至 2030 年期间的复合年增长率为 10.8%。美国癌症切片检查市场的成长归因于多参数磁振造影切片检查活检的日益普及以及影像引导针活检在精准医疗应用中的日益普及。

预计未来几年液态切片行业将呈指数级增长，参与生物製药製造和基因组资料分析的公司不断增加的投资和战略倡议将发挥核心作用。 2022 年 4 月，Global Brain 投资 Craif, Inc.，开发一种用于早期癌症检测的新型非侵入性尿液液态切片。

此外，液态切片的出现、活体组织切片临床应用的不断增加以及遗传性癌症疾病品质和付款的进步是预计在未来几年推动市场成长的一些因素。此外，癌症发生率的上升和老年人口的增加也可能推动市场成长。

此外，基于血液的多癌症早期检测 (MCED) 技术的出现预计将在预测期内提供有利可图的机会。 MCED 代表了未来癌症诊断和治疗方式的模式转移。 MCED 的巨大潜力在于使临床医生从筛检少数癌症转向筛检大量癌症。

GRAIL 和 Exact Sciences 等开发商正在开发 MCED 测试。此外，美国国家癌症美国(NCI) 正在寻找研究和评估 MCED 测试的方法。 NCI 目前正在为 MCED 测试规划临床试验和其他研究机会，并最近向测试开发人员发出了关于他们是否准备好参与研究倡议的资讯请求。

美国切片检查市场的主要企业正在采取多项策略措施来扩大其在市场的份额。市场参与企业进行的主要活动是併购、合作、地理扩张和新产品发布。例如，2022 年 4 月，Medtronic与 GE Healthcare 合作，以满足日益增长的门诊病人护理需求。根据这项倡议，客户可以获得金融解决方案、广泛的产品系列和卓越的服务。

美国癌症切片检查市场报告重点

• 细针抽吸治疗领域占据市场主导地位，2024 年的收入份额最大，为 32.2%。
• 由于定期健康检查和癌症早期发现的需求不断增长，筛检和监测领域在 2024 年占据了市场最大收益占有率。
• 到 2024 年，由于乳癌发生率上升，乳房外科将占据市场的大部分份额。乳癌是女性中最常见的癌症之一，需要频繁进行诊断评估（包括切片检查）以确定疾病的存在和阶段。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章美国切片检查市场变数、趋势和范围

• 市场体系展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 商业环境分析
  • 产业分析 – 波特五力分析
  • PESTLE分析

第 4 章美国癌症切片检查市场：类型业务分析

• 2024 年及 2030 年类型市场占有率
• 类型细分仪表板
• 2018 年至 2030 年按类型分類的市场规模、预测与趋势分析
• 细针穿刺
• 芯切片检查
• 手术切片检查
• 皮肤切片检查/穿刺切片检查
• 其他的

第 5 章美国癌症切片检查市场：原因业务分析

• 2024 年及 2030 年各地区市场占有率
• 原因细分仪表板
• 2018 年至 2030 年按原因分類的市场规模、预测与趋势分析
• 筛检和监测
• 诊断
• 研究与转化研究
• 製药和生物製药的发现和开发

第六章美国癌症切片检查市场：站点业务分析

• 2024 年及 2030 年零件市场占有率
• 身体部位细分仪表板
• 2018 年至 2030 年按身体部位分類的市场规模、预测与趋势分析
• 肝
• 胸部
• 甲状腺
• 摄护腺
• 子宫和子宫颈
• 肾
• 膀胱
• 肺
• 胰臟
• 其他的

第七章 竞争格局

• 参与者概述
• 企业市场分析
• 公司分类
• 战略地图
• 公司简介/上市公司
  • BD（Becton, Dickinson and Company）
  • IZI Medical Products
  • Johnson & Johnson Services, Inc.
  • Argon Medical Devices
  • SPECTRA MEDICAL DEVICES, LLC
  • Medtronic
  • Boston Scientific Corporation
  • CONMED Corporation
  • INRAD, Inc.
  • Thermo Fisher Scientific Inc.

U.S. Cancer Biopsy Market Growth & Trends:

The U.S. cancer biopsy market size is expected to reach USD 20.18 billion by 2030, registering a CAGR of 10.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the U.S. cancer biopsy market is attributed to the rise in the adoption of biopsies based on multi-parametric magnetic resonance imaging and the increasing popularity of image-guided needle biopsies in precision medicine applications.

The liquid biopsy industry is anticipated to expand at an exponential rate in the coming years, wherein increasing investments and strategic initiatives by the companies involved in biopharmaceutical manufacturing & genomic data analysis are anticipated to play a central role. In April 2022, Global Brain invested in Craif, Inc. to develop a novel noninvasive urinary liquid biopsy for the early detection of cancer.

Furthermore, the advent of liquid biopsies, rising clinical implementation of biopsies, and advancements in quality & payment pertaining to genetic cancer diseases are the factors expected to boost the market growth in the coming years. The increasing prevalence of cancer and the growing geriatric population are also likely to fuel market growth.

Moreover, the advent of blood-based multi-cancer early detection (MCED) technologies is going to offer lucrative opportunities during the forecast period. MCED represents a paradigm shift in how cancers will be diagnosed and treated in the future. The great promise of MCED is that it will enable clinicians to convert from screening a few cancers to screening individuals for many cancers.

Companies such as GRAIL, Exact Sciences Corporation are developing MCED tests. In addition, the National Cancer Institute (NCI) is looking at ways to study and evaluate MCED tests. NCI is currently designing clinical trials & other research opportunities for MCED tests, and recently issued a request for information from test developers on their readiness to participate in research initiatives.

Key companies operating in the U.S. cancer biopsy market have adopted several strategic initiatives to reinforce their market presence. Major undertakings by the market participants are mergers & acquisitions, collaborations & partnerships, regional expansions, and new product launches. For instance, in April 2022, Medtronic entered into collaboration with GE Healthcare to address the increasing need for outpatient care. Under this initiative, customers can access financial solutions, extensive product portfolios, and exceptional services.

U.S. Cancer Biopsy Market Report Highlights:

• The fine-needle aspiration segment dominated the market with the largest revenue share of 32.2% in 2024, driven by the increasing prevalence of cancer and a growing preference for minimally invasive procedures.
• The screening & monitoring segment dominated the market with the largest revenue share in 2024, attributable to the rising demand for regular health check-ups and early cancer detection.
• The breast segment held a significant share of the market in 2024, driven by the rising incidence of breast cancer. As one of the most diagnosed cancers among women, breast cancer needs frequent diagnostic assessment, including biopsies, to determine the presence and stage of the disease.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Cause (Application)
  • 1.2.3. Site (Organ)
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Cancer Biopsy Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. U.S. Cancer Biopsy Market: Type Business Analysis

• 4.1. Type Market Share, 2024 & 2030
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
• 4.4. Fine-needle Aspiration
  • 4.4.1. Fine-needle Aspiration Market, 2018 - 2030 (USD Billion)
  • 4.4.2. Pharma-use
    • 4.4.2.1. Pharma-use Market, 2018 - 2030 (USD Billion)
  • 4.4.3. Clinical
    • 4.4.3.1. Clinical Market, 2018 - 2030 (USD Billion)
• 4.5. Core Biopsy
  • 4.5.1. Core Biopsy Market, 2018 - 2030 (USD Billion)
  • 4.5.2. Pharma-use
    • 4.5.2.1. Pharma-use Market, 2018 - 2030 (USD Billion)
  • 4.5.3. Clinical
    • 4.5.3.1. Clinical Market, 2018 - 2030 (USD Billion)
• 4.6. Surgical Biopsy
  • 4.6.1. Surgical Biopsy Market, 2018 - 2030 (USD Billion)
  • 4.6.2. Pharma-use
    • 4.6.2.1. Pharma-use Market, 2018 - 2030 (USD Billion)
  • 4.6.3. Clinical
    • 4.6.3.1. Clinical Market, 2018 - 2030 (USD Billion)
• 4.7. Skin Biopsy /Punch Biopsy
  • 4.7.1. Skin Biopsy /Punch Biopsy Market, 2018 - 2030 (USD Billion)
  • 4.7.2. Pharma-use
    • 4.7.2.1. Pharma-use Market, 2018 - 2030 (USD Billion)
  • 4.7.3. Clinical
    • 4.7.3.1. Clinical Market, 2018 - 2030 (USD Billion)
• 4.8. Others
  • 4.8.1. Others Market, 2018 - 2030 (USD Billion)
  • 4.8.2. Pharma-use
    • 4.8.2.1. Pharma-use Market, 2018 - 2030 (USD Billion)
  • 4.8.3. Clinical
    • 4.8.3.1. Clinical Market, 2018 - 2030 (USD Billion)

Chapter 5. U.S. Cancer Biopsy Market: Cause (Application) Business Analysis

• 5.1. Cause (Application) Market Share, 2024 & 2030
• 5.2. Cause (Application) Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Cause (Application), 2018 to 2030 (USD Billion)
• 5.4. Screening & Monitoring
  • 5.4.1. Screening & Monitoring Market, 2018 - 2030 (USD Billion)
• 5.5. Diagnostics
  • 5.5.1. Diagnostics Market, 2018 - 2030 (USD Billion)
• 5.6. Investigational & Translational Research
  • 5.6.1. Investigational & Translational Research Market, 2018 - 2030 (USD Billion)
• 5.7. Pharma & Biopharma Discovery & Development
  • 5.7.1. Pharma & Biopharma Discovery & Development Market, 2018 - 2030 (USD Billion)

Chapter 6. U.S. Cancer Biopsy Market: Site (Organ) Business Analysis

• 6.1. Site (Organ) Market Share, 2024 & 2030
• 6.2. Site (Organ) Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Site (Organ), 2018 to 2030 (USD Billion)
• 6.4. Liver
  • 6.4.1. Liver, 2018 - 2030 (USD Billion)
• 6.5. Breast
  • 6.5.1. Breast Market, 2018 - 2030 (USD Billion)
• 6.6. Thyroid
  • 6.6.1. Thyroid Market, 2018 - 2030 (USD Billion)
• 6.7. Prostate Gland
  • 6.7.1. Prostate Gland Market, 2018 - 2030 (USD Billion)
• 6.8. Uterus & Cervix
  • 6.8.1. Uterus & Cervix Market, 2018 - 2030 (USD Billion)
• 6.9. Kidney
  • 6.9.1. Kidney Market, 2018 - 2030 (USD Billion)
• 6.10. Bladder
  • 6.10.1. Bladder Market, 2018 - 2030 (USD Billion)
• 6.11. Lungs
  • 6.11.1. Lungs Market, 2018 - 2030 (USD Billion)
• 6.12. Pancreas
  • 6.12.1. Pancreas Market, 2018 - 2030 (USD Billion)
• 6.13. Others
  • 6.13.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. BD (Becton, Dickinson and Company)
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Type Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. IZI Medical Products
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Type Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Johnson & Johnson Services, Inc.
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Type Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Argon Medical Devices
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Type Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. SPECTRA MEDICAL DEVICES, LLC
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Type Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Medtronic
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Type Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Boston Scientific Corporation
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Type Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. CONMED Corporation
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Type Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. INRAD, Inc.
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Type Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Thermo Fisher Scientific Inc.
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Type Benchmarking
    • 7.5.10.4. Strategic Initiatives

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. U.S. cancer biopsy market, by type, 2018 - 2030 (USD Billion)
• Table 4. U.S. cancer biopsy market, by cause (application), 2018 - 2030 (USD Billion)
• Table 5. U.S. cancer biopsy market, by site (organ), 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 U.S. cancer biopsy market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Type outlook (USD Billion)
• Fig. 10 Cause (application) outlook (USD Billion)
• Fig. 11 Site (organ) outlook (USD Billion)
• Fig. 12 Competitive landscape
• Fig. 13 U.S. cancer biopsy market dynamics
• Fig. 14 U.S. cancer biopsy market: Porter's five forces analysis
• Fig. 15 U.S. cancer biopsy market: PESTLE analysis
• Fig. 16 U.S. cancer biopsy market: Type segment dashboard
• Fig. 17 U.S. cancer biopsy market: Type market share analysis, 2024 & 2030
• Fig. 18 Fine-needle aspiration market, 2018 - 2030 (USD Billion)
• Fig. 19 Pharma-use market, 2018 - 2030 (USD Billion)
• Fig. 20 Clinical market, 2018 - 2030 (USD Billion)
• Fig. 21 Core biopsy market, 2018 - 2030 (USD Billion)
• Fig. 22 Pharma-use market, 2018 - 2030 (USD Billion)
• Fig. 23 Clinical market, 2018 - 2030 (USD Billion)
• Fig. 24 Surgical biopsy market, 2018 - 2030 (USD Billion)
• Fig. 25 Pharma-use market, 2018 - 2030 (USD Billion)
• Fig. 26 Clinical market, 2018 - 2030 (USD Billion)
• Fig. 27 Skin biopsy /punch biopsy market, 2018 - 2030 (USD Billion)
• Fig. 28 Pharma-use market, 2018 - 2030 (USD Billion)
• Fig. 29 Clinical market, 2018 - 2030 (USD Billion)
• Fig. 30 Others market, 2018 - 2030 (USD Billion)
• Fig. 31 Pharma-use market, 2018 - 2030 (USD Billion)
• Fig. 32 Clinical market, 2018 - 2030 (USD Billion)
• Fig. 33 U.S. cancer biopsy market: Cause (application) segment dashboard
• Fig. 34 U.S. cancer biopsy market: Cause (application) market share analysis, 2024 & 2030
• Fig. 35 Screening & monitoring market, 2018 - 2030 (USD Billion)
• Fig. 36 Diagnostics market, 2018 - 2030 (USD Billion)
• Fig. 37 Investigational & translational research market, 2018 - 2030 (USD Billion)
• Fig. 38 Pharma & biopharma discovery & development market, 2018 - 2030 (USD Billion)
• Fig. 39 U.S. cancer biopsy market: Site (organ) segment dashboard
• Fig. 40 U.S. cancer biopsy market: Site (organ) market share analysis, 2024 & 2030
• Fig. 41 Liver market, 2018 - 2030 (USD Billion)
• Fig. 42 Breast market, 2018 - 2030 (USD Billion)
• Fig. 43 Thyroid market, 2018 - 2030 (USD Billion)
• Fig. 44 Prostate gland market, 2018 - 2030 (USD Billion)
• Fig. 45 Uterus & cervix market, 2018 - 2030 (USD Billion)
• Fig. 46 Kidney market, 2018 - 2030 (USD Billion)
• Fig. 47 Bladder market, 2018 - 2030 (USD Billion)
• Fig. 48 Lungs market, 2018 - 2030 (USD Billion)
• Fig. 49 Pancreas market, 2018 - 2030 (USD Billion)
• Fig. 50 Others market, 2018 - 2030 (USD Billion)
• Fig. 51 Company categorization
• Fig. 52 Company market position analysis
• Fig. 53 Strategic framework